Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
SBBP Stock Summary
In the News
Xeris Pharmaceuticals Completes Acquisition of Strongbridge Biopharma
CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (“Xeris”), a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced that it has successfully completed the previously announced acquisition of Strongbridge Biopharma plc (Nasdaq: SBBP) (“Strongbridge”). Under the terms of the acquisition agreement, the businesses of Xeris and Strongbridge are now combined under Xeris Biopharma Holdin
Strongbridge Biopharma plc Announces Completion of Acquisition by Xeris Pharmaceuticals, Inc.
DUBLIN, Ireland and TREVOSE, Pa., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ: SBBP) (the “Company” or “Strongbridge”) today announced that the High Court of Ireland (the "Court") has approved the previously announced proposed acquisition of Strongbridge by Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) (“Xeris”) by means of a scheme of arrangement (the "Scheme") under Chapter 1 of Part 9 of the Irish Companies Act 2014 (the "Act").
Strongbridge Biopharma plc Announces Court Hearing Date to Approve Proposed Acquisition by Xeris Pharmaceuticals, Inc.
DUBLIN, Ireland and TREVOSE, Pa., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ: SBBP) (the “Company” or “Strongbridge”) today announced that the High Court of Ireland (the “Court”) has set the date of the final court hearing to sanction the proposed acquisition of Strongbridge by Xeris Pharmaceuticals, Inc. (“Xeris”) by means of scheme of arrangement (the “Scheme”) under Chapter 1 of Part 9 of the Irish Companies Act 2014 (the “Act”).
Strongbridge Biopharma plc Announces Shareholder Approval of Proposed Acquisition by Xeris Pharmaceuticals, Inc.
DUBLIN, Ireland and TREVOSE, Pa., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ: SBBP) (the “Company” or “Strongbridge”) today announced that its shareholders have voted to approve the previously announced proposed acquisition of Strongbridge by Xeris Pharmaceuticals, Inc. (NASDAQ: XERS) (“Xeris”). As described below, at least 99 percent of the votes cast at both a special court-ordered meeting of shareholders (the “Court Meeting”) and at an extraordinary general meeting of shareholders (the “EGM”) were in favor of the transaction, representing (in each case) approximately 67 percent of the shares outstanding and eligible to be voted at each of the Strongbridge shareholder meetings held on September 8, 2021 in Pennsylvania, United States of America. Upon close of the transaction, the business of Xeris and Strongbridge will be combined under an entity called Xeris Biopharma Holdings, Inc. (“Xeris Biopharma Holdings” or “HoldCo”).
Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Strongbridge Biopharma plc Shareholders Vote “FOR” the Transaction With Xeris
Glass Lewis Joins ISS in Recommending Strongbridge Shareholders Vote “FOR” Transaction with Xeris
Leading Independent Proxy Advisory Firm ISS Recommends Strongbridge Biopharma plc Shareholders Vote “FOR” the Transaction With Xeris
Strongbridge Urges Shareholders to Vote “FOR” All Transaction-Related Proposals Strongbridge Urges Shareholders to Vote “FOR” All Transaction-Related Proposals
Strongbridge Biopharma (SBBP) Reports Q2 Loss, Tops Revenue Estimates
Strongbridge Biopharma (SBBP) delivered earnings and revenue surprises of 20.00% and 13.69%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Strongbridge Biopharma plc Reports Second Quarter 2021 Financial Results and Provides Corporate Update
~ Reports KEVEYIS ® (dichlorphenamide) Second Quarter 2021 Revenue of $10.0 Million, a 28 Percent Increase Compared to $7.8 Million of Revenue During Second Quarter of 2020 ~
Strongbridge Biopharma plc Announces Commencement of Mailing of Proxy Statement
DUBLIN, Ireland and TREVOSE, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP) (“Strongbridge”), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced for the purposes of the Irish Takeover Panel Act, 1997, Takeover Rules 2013 (the “Irish Takeover Rules”), that the definitive joint proxy statement/prospectus of Strongbridge (the “Proxy Statement”), which also constitutes a scheme circular under Irish law, is being sent as of July 30, 2021 to Strongbridge shareholders.
Strongbridge Biopharma plc Provides Announcement Under the Irish Takeover Rules for Relevant Securities in Issue
DUBLIN, Ireland and TREVOSE, Pa., July 29, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP) (“Strongbridge”), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced in accordance with Rule 2.10 of the Irish Takeover Rules that, as of the close of business on July 28, 2021, Strongbridge's issued share capital, excluding treasury shares, is comprised of 67,828,952 ordinary shares with a par value of $0.01 per share. Strongbridge's ordinary shares are traded on the Nasdaq under the symbol SBBP. The International Securities Identification Number (ISIN) of the Strongbridge ordinary shares is IE00BYZ5XL97.
SBBP Financial details
SBBP Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2020-12-31
Metric | History | 2016-12-31 | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0.19 | 0.36 | 0.39 | 0.55 | |
Net income per share | -2.26 | -3.11 | 0.64 | -0.89 | -0.8 | |
Operating cash flow per share | -1.47 | -1.24 | -1.7 | -0.81 | -0.68 | |
Free cash flow per share | -1.47 | -1.24 | -1.71 | -0.81 | -0.68 | |
Cash per share | 3.1 | 1.57 | 2.46 | 1.41 | 1.56 | |
Book value per share | 3.11 | -0.33 | 2.27 | 1.3 | 1.17 | |
Tangible book value per share | -0.05 | -1.49 | 1.52 | 0.72 | 0.68 | |
Share holders equity per share | 3.11 | -0.33 | 2.27 | 1.3 | 1.17 | |
Interest debt per share | 0.86 | 1.15 | 0.25 | 0 | 0.33 | |
Market cap | 51.72M | 264.95M | 222.77M | 115.75M | 136.34M | |
Enterprise value | 3.32M | 245.23M | 100.28M | 60.17M | 67.01M | |
P/E ratio | -1.06 | -2.33 | 6.99 | -2.34 | -3.02 | |
Price to sales ratio | 0 | 37.6 | 12.36 | 5.33 | 4.44 | |
POCF ratio | -1.63 | -5.84 | -2.63 | -2.58 | -3.58 | |
PFCF ratio | -1.63 | -5.84 | -2.62 | -2.58 | -3.57 | |
P/B Ratio | 0.77 | -22.24 | 1.97 | 1.6 | 2.08 | |
PTB ratio | 0.77 | -22.24 | 1.97 | 1.6 | 2.08 | |
EV to sales | 0 | 34.8 | 5.56 | 2.77 | 2.18 | |
Enterprise value over EBITDA | -0.06 | -2.4 | 1.92 | -1.41 | -1.73 | |
EV to operating cash flow | -0.1 | -5.41 | -1.19 | -1.34 | -1.76 | |
EV to free cash flow | -0.1 | -5.41 | -1.18 | -1.34 | -1.76 | |
Earnings yield | -0.94 | -0.43 | 0.14 | -0.43 | -0.33 | |
Free cash flow yield | -0.61 | -0.17 | -0.38 | -0.39 | -0.28 | |
Debt to equity | 0.28 | -3.17 | 0 | 0 | 0.26 | |
Debt to assets | 0.13 | 0.36 | 0 | 0 | 0.14 | |
Net debt to EBITDA | 0.95 | 0.19 | -2.35 | 1.31 | 1.79 | |
Current ratio | 4.24 | 4.87 | 7.67 | 3.44 | 4.37 | |
Interest coverage | -1.74K | -12.29 | -6.55 | 0 | -32.31 | |
Income quality | 0.65 | 0.4 | -2.66 | 0.91 | 0.85 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 5.15 | 3.51 | 2.11 | 1.33 | |
Research and developement to revenue | 0 | 2.45 | 1.41 | 1.42 | 0.84 | |
Intangibles to total assets | 0.5 | 0.41 | 0.22 | 0.28 | 0.23 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | -0.02 | 0 | 0 | |
Capex to depreciation | 0 | 0 | -0.05 | -0.01 | 0 | |
Stock based compensation to revenue | 0 | 0.73 | 0.43 | 0.4 | 0.24 | |
Graham number | 12.56 | 4.77 | 5.72 | 5.12 | 4.6 | |
ROIC | -0.39 | -2.08 | -0.71 | -0.9 | -0.51 | |
Return on tangible assets | -0.7 | -1.84 | 0.24 | -0.58 | -0.48 | |
Graham Net | -0.15 | -1.56 | 1.37 | 0.64 | 0.62 | |
Working capital | 51.64M | 48.33M | 115.05M | 59.25M | 71.22M | |
Tangible asset value | -1.18M | -54.33M | 75.57M | 39.83M | 38.26M | |
Net current asset value | -2.96M | -55.03M | 74.97M | 38.1M | 36.86M | |
Invested capital | 0.28 | -3.17 | 0 | 0 | 0.26 | |
Average receivables | 382K | 1.17M | 1.61M | 1.96M | 2.55M | |
Average payables | 1.94M | 1.17M | 1.22M | 2.26M | 2.41M | |
Average inventory | 0 | 255.5K | 2.23M | 2.97M | 1.55M | |
Days sales outstanding | 0 | 82.06 | 32.92 | 38.48 | 33.27 | |
Days payables outstanding | 0 | 306.92 | 108.42 | 318.11 | 244.71 | |
Days of inventory on hand | 0 | 125.77 | 361.34 | 190.33 | 182 | |
Receivables turnover | 0 | 4.45 | 11.09 | 9.49 | 10.97 | |
Payables turnover | 0 | 1.19 | 3.37 | 1.15 | 1.49 | |
Inventory turnover | 0 | 2.9 | 1.01 | 1.92 | 2.01 | |
ROE | -0.73 | 9.53 | 0.28 | -0.69 | -0.69 | |
Capex per share | 0 | 0 | -0.01 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2021-06-30 for Q2
Metric | History | 2020-06-30 | 2020-09-30 | 2020-12-31 | 2021-03-31 | 2021-06-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.14 | 0.14 | 0.15 | 0.12 | 0.15 | |
Net income per share | -0.32 | -0.06 | -0.21 | -0.18 | -0.2 | |
Operating cash flow per share | -0.22 | -0.1 | -0.09 | -0.2 | -0.15 | |
Free cash flow per share | -0.22 | -0.1 | -0.09 | -0.2 | -0.15 | |
Cash per share | 1.1 | 1.46 | 1.56 | 1.1 | 0.94 | |
Book value per share | 0.88 | 1.33 | 1.17 | 0.83 | 0.66 | |
Tangible book value per share | 0.33 | 0.82 | 0.68 | 0.44 | 0.29 | |
Share holders equity per share | 0.88 | 1.33 | 1.17 | 0.83 | 0.66 | |
Interest debt per share | 0.13 | 0.14 | 0.32 | 0.28 | 0.28 | |
Market cap | 205.26M | 117.82M | 136.34M | 185.96M | 200.93M | |
Enterprise value | 152.36M | 43.71M | 66.09M | 129.88M | 155.3M | |
P/E ratio | -2.97 | -9.32 | -2.85 | -3.94 | -3.79 | |
Price to sales ratio | 26.45 | 14.6 | 16.57 | 22.19 | 20.01 | |
POCF ratio | -16.91 | -20.46 | -27.27 | -13.88 | -20.45 | |
PFCF ratio | -16.91 | -20.42 | -27.27 | -13.87 | -20.45 | |
P/B Ratio | 4.29 | 1.58 | 2.08 | 3.33 | 4.53 | |
PTB ratio | 4.29 | 1.58 | 2.08 | 3.33 | 4.53 | |
EV to sales | 19.63 | 5.42 | 8.03 | 15.5 | 15.47 | |
Enterprise value over EBITDA | -9.68 | -32.14 | -6.53 | -13.31 | -13.92 | |
EV to operating cash flow | -12.56 | -7.59 | -13.22 | -9.7 | -15.8 | |
EV to free cash flow | -12.56 | -7.58 | -13.22 | -9.69 | -15.8 | |
Earnings yield | -0.08 | -0.03 | -0.09 | -0.06 | -0.07 | |
Free cash flow yield | -0.06 | -0.05 | -0.04 | -0.07 | -0.05 | |
Debt to equity | 0.15 | 0.1 | 0.26 | 0.32 | 0.41 | |
Debt to assets | 0.07 | 0.06 | 0.14 | 0.16 | 0.19 | |
Net debt to EBITDA | 3.36 | 54.5 | 6.94 | 5.75 | 4.09 | |
Current ratio | 3.39 | 4.51 | 4.37 | 3.63 | 3 | |
Interest coverage | -38.25 | -18.33 | -18.57 | -12.88 | -16.13 | |
Income quality | 0.7 | 1.82 | 0.42 | 1.13 | 0.74 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 1.24 | 1.14 | 1.41 | 1.31 | 1.59 | |
Research and developement to revenue | 0.79 | 0.84 | 0.65 | 0.7 | 0.54 | |
Intangibles to total assets | 0.31 | 0.24 | 0.23 | 0.24 | 0.26 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | -0.01 | 0 | -0.01 | 0 | |
Stock based compensation to revenue | 0.23 | 0.26 | 0.22 | 0.27 | 0.21 | |
Graham number | 2.51 | 1.3 | 2.37 | 1.81 | 1.7 | |
ROIC | -0.1 | -0.37 | -0.12 | -0.12 | -0.21 | |
Return on tangible assets | -0.25 | -0.04 | -0.13 | -0.14 | -0.18 | |
Graham Net | 0.24 | 0.74 | 0.62 | 0.36 | 0.22 | |
Working capital | 46.54M | 68M | 71.22M | 57.69M | 46.74M | |
Tangible asset value | 18.01M | 45.97M | 38.26M | 29.76M | 19.56M | |
Net current asset value | 16.26M | 44.28M | 36.86M | 27.46M | 17.69M | |
Invested capital | 0.15 | 0.1 | 0.26 | 0.32 | 0.41 | |
Average receivables | 2.79M | 2.89M | 2.85M | 2.82M | 3.21M | |
Average payables | 3.62M | 1.77M | 1.54M | 3.61M | 3.19M | |
Average inventory | 1.33M | 1.22M | 1.11M | 1.06M | 1.05M | |
Days sales outstanding | 33.46 | 32.28 | 30.65 | 30.56 | 32.09 | |
Days payables outstanding | 448.17 | 350.29 | 301.97 | 1.26K | 122.38 | |
Days of inventory on hand | 301.15 | 246.18 | 224.59 | 220.51 | 212.18 | |
Receivables turnover | 2.69 | 2.79 | 2.94 | 2.95 | 2.8 | |
Payables turnover | 0.2 | 0.26 | 0.3 | 0.07 | 0.74 | |
Inventory turnover | 0.3 | 0.37 | 0.4 | 0.41 | 0.42 | |
ROE | -0.36 | -0.04 | -0.18 | -0.21 | -0.3 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
SBBP Frequently Asked Questions
What is Strongbridge Biopharma plc stock symbol ?
Strongbridge Biopharma plc is a US stock , located in Trevose of Pennsylvania and trading under the symbol SBBP
What is Strongbridge Biopharma plc stock quote today ?
Strongbridge Biopharma plc stock price is $2 today.
Is Strongbridge Biopharma plc stock public?
Yes, Strongbridge Biopharma plc is a publicly traded company.